Nevertheless, combination therapy with a BRAF inhibitor and MEK inhibitor has shown encouraging efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer. The gene discussed is MAP2K7; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.